gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ARQTHealthcarePharmaceuticals

Arcutis Biotherapeutics, Inc. Common Stock (ARQT)

$34.05+6.41%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$33.31▲ 34.55% in range
Nov 3, 2025Low $19.50 · High $33.31Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Arcutis Biotherapeutics closed at $34.05 on Nov 4, up 6.41% — matching its 52-week closing high. Volume of 2.7M shares was 1.22× its 20-day average (close to normal).

Split-adjusted performance: +42.3% over one month, +40.9% over six months, +37.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $129.86M, up 59.3% from a year earlier, with a net margin of 11.6%.

Short interest was 20.5M shares at the Oct 15 settlement, down 5.5% from the prior report (18.0% of float, 9.8 days to cover).

Market cap$4.28B125.7M shares
Revenue · quarter$129.9M+59.3% YoY
Diluted EPS$0.11—
P/E · TTM150.1×P/S 9.2×
Net margin11.6%Gross 91.6%
Dividend yieldNone
52-week range19.50 – 34.050.0% from high
Volume2.7M1.22× 20-day avg
Volatility · 60d54.8%Annualised
Short % of float18.0%9.8 days to cover
Net cash$129.7MCash $238.6M
Next earnings—Not scheduled
Split-adjusted performance
1W +8.3%1M +42.3%3M +28.8%6M +40.9%YTD +17.3%1Y +37.5%3Y +1380.4%5Y +61.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum90
Revenue growth80
Net margin81
Value (low P/E)3
Size89

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short20.5M−5.5% vs prior
Days to cover9.8Settled Oct 15
% of float18.0%
Short vol. 10d52.2%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ARQTArcutis Biotherapeutics$34.05+6.41%+40.9%+59.3%11.6%150.1$4.28B
LQDALiquidia$47.38+12.27%+12.4%+1842.7%43.5%30.6$4.24BCompare
DFTXDefinium Therapeutics$32.70−2.13%+39.6%———$4.39BCompare
EWTXEdgewise Therapeutics$37.53−0.40%+1.5%———$4.08BCompare
ABCLAbCellera Biologics$12.28+0.82%+143.7%−76.3%−1368.6%—$3.98BCompare
TNGXTango Therapeutics$23.18+0.04%−1.9%−100.0%——$3.91BCompare
DNTHDianthus Therapeutics$85.81+3.76%−5.1%+294.3%−6598.6%—$4.80BCompare
XENEXenon Pharmaceuticals$39.19+2.51%−33.1%———$3.80BCompare
PBLSParabilis Medicines$30.36+3.79%——−45239.9%—$3.75BCompare

News about Arcutis Biotherapeutics

All news →
Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research · Oct 28, 2026▲ PositiveArcutis Appoints Rob Scott, MD to Board of DirectorsGlobeNewswire Inc. · Oct 28, 2026▲ PositiveArcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026GlobeNewswire Inc. · Oct 21, 2026▲ PositiveArcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall ClinicalGlobeNewswire Inc. · Oct 9, 2026▲ PositiveArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · Oct 2, 2026Neutral

Quick answers

What does Arcutis Biotherapeutics do?
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions.
What is ARQT's market cap?
$4.28B, based on the Nov 4 close of $34.05.
What is ARQT's P/E ratio?
150.1× trailing-twelve-month earnings of $28.52M.
Does Arcutis Biotherapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ARQT is sold short?
20.5M shares, 18.0% of float, as of Oct 15, 2026.
What sector is ARQT in?
Healthcare, in the Pharmaceuticals industry.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

HQ: Westlake Village, CA354 employeesListed Jan 31, 2020arcutis.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology